ACM
SBFM

Altium Capital Management’s Sunshine Biopharma SBFM Stock Holding History

Altium Capital Management’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,047
Closed -$96.4K – 15
2025
Q1 		$96.4K Buy
+5,047
New +$127K 0.23% 23

Other funds holding SBFM

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Altium Capital Management's SBFM Position: Q2 2025 in Review

Altium Capital Management sold out of Sunshine Biopharma (SBFM) in Q2 2025, closing a stake of 5,047 shares — an estimated $96.4K sold.

Altium Capital Management first reported a position in SBFM in Q1 2025 and held it in 1 quarter. The position peaked at $96.4K in Q1 2025. 9 funds tracked by Wall St. Rank hold SBFM as of Q2 2025.

  • Altium Capital Management reported no remaining Sunshine Biopharma position as of Q2 2025 after selling out during the quarter.
  • Altium Capital Management sold 5,047 Sunshine Biopharma shares in Q2 2025, an estimated $96.4K.
  • Altium Capital Management first reported a position in Sunshine Biopharma in Q1 2025 and held it in 1 quarter.
  • Altium Capital Management's Sunshine Biopharma position peaked at $96.4K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.